[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522726":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":48,"responsibleParty":65,"collaborators":10,"id":68,"slug":10,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Centre for Addiction and Mental Health","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"COVID-DNP",null,"Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).",[13,14,15],"Other: [11C]DTBZ PET scan","Other: [18F]SDM8 PET scan","Other: MRI scan",{"label":17,"type":10,"description":18,"interventionNames":19},"Healthy Control","Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.",[13,14,15],[21,25,29],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"[11C]DTBZ PET scan","One \\[11C\\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)",[9,17],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"[18F]SDM8 PET scan","One \\[18F\\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)",[9,17],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"MRI scan","One MRI scan",[9,17],[34],{"name":35,"affiliation":5,"role":36},"Jeffrey Meyer, M.D., PhD","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Karida Liu","CONTACT","416-535-8501","39674","liuyuhan0830@gmail.com",{"name":45,"role":40,"phone":41,"phoneExt":46,"email":47},"Jeffrey Meyer","34007","jeffrey.meyer@utoronto.ca",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":10,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Toronto","Ontario","Canada",{"type":55,"coordinates":56},"Point",[57,58],-79.39864,43.70643,{"lat":58,"lon":57},[61],{"name":62,"role":40,"phone":63,"phoneExt":10,"email":64},"Yuhan Liu","(416) 535-8501 ext. 39674","yuhan.liu@camh.ca",{"type":36,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jeff Meyer","Scientist and Head, Neurochemical Imaging Program in Mood and Anxiety Disorders, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute","100522726",false,"NCT06086366","Presynaptic Imaging in Major Depressive Episodes After COVID-19","PCOV","Inclusion Criteria:\n\n* New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See \"Positive COVID-19 diagnosis\" listed after inclusion\u002Fexclusion criteria for a description of how this is determined.\n* Age 18 to 75.\n* Good general physical health with no active medical conditions based on self-report (except migraine or PASC).\n\nExclusion Criteria:\n\n* Use of antidepressants in the previous month (6 weeks for fluoxetine).\n* Use of stimulant medication affecting dopamine release in the previous month\n* Use of antipsychotics in the previous month\n* History of neurological disease (except migraine, and PASC) based on self-report\n* Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report\n* Presence of cigarette smoking in the past two months, based on self-report\n* Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)\n* Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)\n* Positive urine drug or cotinine screen at any timepoint during the study\n* History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)\n* Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan)\n* Breastfeeding (for females)\n* Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report\n* Claustrophobia, based on self-report\n* Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns)\n* Presence of metal implant, object or electrical devices that are contraindicated for MRI, based on self-report\n* Severe allergic reaction to alcohol",true,"ALL","18 Years","75 Years",{"count":79,"type":80},90,"ESTIMATED","OBSERVATIONAL","The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.",[84,85,86],"Long COVID","Major Depressive Disorder","Major Depressive Episode",[88,84,85,86,89,90],"PET","Anhedonia","Dopamine Neuron Loss","2026-02-09",{"date":93,"type":94},"2026-02-11","ACTUAL",{"date":96,"type":94},"2023-08-22",{"date":98,"type":80},"2028-09-10",{"name":5,"class":6},1]